Immunovant, Inc.
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development | $456.7M+26.5% | $360.9M+69.5% | $212.9M+32.9% | $160.3M+57.4% | $101.8M |
| Acquired in-process research and development | $0 | $0-100.0% | $12.5M+25.0% | $10.0M | $0 |
| General and administrative | $76.2M-1.3% | $77.2M+34.8% | $57.3M+19.3% | $48.0M-11.4% | $54.2M |
| Total operating expenses | $532.9M+21.6% | $438.2M+55.0% | $282.7M+29.5% | $218.3M+39.9% | $156.0M |
| Interest income, net | -$25.3M-2.4% | -$24.7M+0.9% | -$24.9M-229.2% | -$7.6M | $0 |
| Other (income) expense, net | -$2.2M-363.1% | -$471K-146.7% | $1.0M+298.4% | $253K-67.6% | $781K |
| Loss before provision for income taxes | -$505.4M-22.4% | -$412.9M-59.6% | -$258.8M-22.7% | -$211.0M-34.5% | -$156.8M |
| Provision for income taxes | $215K-75.9% | $891K+57.1% | $567K+6200.0% | $9K+110.7% | -$84K |
| Net loss | -$505.6M-22.2% | -$413.8M-59.6% | -$259.3M-22.9% | -$211.0M-34.6% | -$156.7M |
| Net loss per common share — basic (in dollars per share) | -$2770.00-1.5% | -$2730.00-45.2% | -$1880.00-9.9% | -$1710.00-19.6% | -$1430.00 |
| Net loss per common share — diluted (in dollars per share) | -$2770.00-1.5% | -$2730.00-45.2% | -$1880.00-9.9% | -$1710.00-19.6% | -$1430.00 |
| Weighted average common shares outstanding — basic (in shares) | 182.42B+20.4% | 151.57B+9.8% | 138.10B+12.2% | 123.08B+12.2% | 109.68B |
| Weighted average common shares outstanding — diluted (in shares) | 182.42B+20.4% | 151.57B+9.8% | 138.10B+12.2% | 123.08B+12.2% | 109.68B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Immunovant reports IMVT-1402 showed 72.7% ACR20 response in difficult-to-treat rheumatoid arthritis trial with $902.1M cash runway through potential Graves' disease launch
“Current cash balance provides runway to the potential launch of IMVT-1402 in GD.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | 2026-05-29 | Fromkin Andrew J. | Director | Sale | 222.0K | $33.51 | $7.44M | 74.4K | View | |
| 2026-05-20 | 2026-05-22 | Gloria Melanie | Chief Operating Officer | Sale | 3,115 | $32.45 | $101K | 242.1K | View | |
| 2026-05-20 | 2026-05-20 | Pande Atul | Director | Sale | 6,000 | $32.00 | $192K | 116.7K | View | |
| 2026-05-01 | 2026-05-01 | Susman Robert Graham | Director | Sale | 2,502 | $27.17 | $68K | 36.4K | View | |
| 2026-04-23 | 2026-04-24 | Girao Tiago | Chief Financial Officer | Sale | 25.8K | $29.62 | $763K | 247.6K | View |
Informational purposes only, not investment advice.